A 29-forward-P/E Amazon is quietly building the most defensible AI cost-savings engine in corporate America, while 48-forward-P/E Hims & Hers is locking in Gen-Z lifetime value inside a $250 billion virtual-care shift. Both risk-reward setups skew sharply to the upside through 2027.
Why Amazon’s AI Pivot Is Different This Time
Amazon’s $2.56 trillion market cap masks a stealth re-rating already under way inside Amazon Web Services. While headlines obsess over GPU shortages, AWS is monetizing the bottleneck itself: it rents the chips, sells the inference platform, and—crucially—designs custom silicon to undercut Nvidia on cost per training hour.
CEO Andy Jassy’s June internal memo, confirmed by The Motley Fool, projects AI-driven office automation alone could eliminate 600,000 roles by 2033. Apply the company’s Q3 annualized operating expense run-rate of roughly $651 billion and even a 5% head-count reduction drops $32 billion straight to the bottom line—enough to add more than $12 per share in net earnings.
Wall Street’s 2027 EPS consensus sits at $7.40, a 34% uplift versus 2025. That pegs the forward multiple at 29—barely a market premium for a cash-flow machine that could compound at 20%-plus once the cost lever is pulled.
Hims & Hers: Telehealth’s Brand Moat at Half the Price of Loss-Making Rivals
While software gets the AI glory, healthcare virtualization is a $250 billion prize hiding in plain sight. Hims & Hers is already capturing share with a marketing spend per acquired customer that undercuts even heavily subsidized peers by nearly 40%, according to company filings cited by The Motley Fool.
The hook: sexual wellness, mental-health and hair-loss scripts delivered as chewables, gummies or topical pens—products legacy telehealth players dismissed as “gimmicks” yet which carry gross margins above 70%. Pair that with a pending distribution deal for Novo Nordisk’s Wegovy and oral GLP-1 pipeline and you get a direct-to-consumer conduit into the fastest-growing prescription category on earth.
Revenue just printed 49% year-over-year growth to $600 million in Q3. At a 48-forward-P/E the stock looks frothy—until you realize the same multiple compressed to 25 on 2027 analyst estimates that still model 35% top-line CAGR. That’s a 0.7 PEG ratio for a company with negative working-capital needs and 65% incremental gross margins.
Risk Checklist: What Could Go Wrong
- Amazon: Regulatory push-back on job-displacement optics or cloud price wars could delay margin expansion.
- Hims & Hers: FDA advertising scrutiny or a GLP-1 supply shock might slow subscriber adds.
Both risks are measurable and already discounted in Street scenarios that still yield double-digit IRRs even under bear-case assumptions.
Portfolio Action: Scale In, Don’t Chase
For Amazon, doubling up inside tax-advantaged accounts captures the AI opex leverage before the consensus catches up. Use any broad-market pullback toward $165–$170 as entry.
Hims & Hers is more volatile; accumulate on weekly closes above the 200-day moving average (currently $21.50) and size the position so that a 50% drawdown does not breach more than 2% of total portfolio risk.
Hold both through at least 2027—long enough for AWS AI economics and telehealth’s demographic tailwind to compound, but short enough to re-evaluate before the next capital-expenditure cycle peaks.
Bottom line: In a market starved for durable growth at reasonable prices, Amazon gives you mega-cap safety with a cost-take-out catalyst, while Hims & Hers offers small-cap torque inside a secular shift. Doubling down on either—or both—tilts the odds of beating the S&P 500 decisively in your favor.
Stay ahead of the tape—bookmark onlytrustedinfo.com for the fastest, most authoritative take on every market-moving headline.
